Mitchell G. Weatherly
77 IP cases indexed. Covers patent matters.
Cases Presided Over
77 cases indexed | Page 3 of 3
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
The PTAB found all challenged claims unpatentable by a preponderance of the evidence. The Petitioner successfully argued that combining prior art references (Lundahl and Larsen) rendered the illuminator system obvious to a Person Having Ordinary Skill in the Art (POSITA).
Silicon Motion Inc. et al. v.K. Mizra LLC
Silicon Motion and K. Mizra settled their IPR dispute over U.S. Patent 9,160,466. The Board terminated the proceeding without a merits decision, treating the settlement agreement as confidential.
Silicon Motion Inc. et al. v.K. Mizra LLC
Silicon Motion Inc. successfully convinced the PTAB to institute an IPR against K. Mizra LLC's patent, arguing that the technology for high-speed digital communication channel calibration was obvious over various prior art references. The Board found a reasonable likelihood of prevailing on multiple grounds of obviousness (103).
Tesla, Inc. v.Charge Fusion Technologies, LLC
Tesla successfully challenged Charge Fusion Technologies' patent claims in a PTAB institution decision. The Board found sufficient motivation to combine prior art references, rendering numerous independent and dependent claims obvious under 35 U.S.C. § 103. This outcome significantly weakens the asserted patent portfolio for Charge Fusion.
Tesla Inc. v.Charge Fusion Technologies, LLC
Tesla Inc.'s petition against Charge Fusion Technologies, LLC was instituted by the PTAB, finding a reasonable likelihood that the patent claims are unpatentable as obvious. The Board focused on how prior art references could combine to render independent claims obvious, specifically regarding charging system features.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom settled their IPR dispute over U.S. Patent 9,801,541, filing a joint motion that led the PTAB to terminate the proceeding and keep the settlement agreement confidential.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care successfully petitioned to institute IPR proceedings against DexCom regarding claims related to remote patient monitoring and glucose management. The PTAB found sufficient evidence that the petitioner met its burden of demonstrating a reasonable likelihood of prevailing on multiple grounds (102 and 103).
Head Sport GmbH v.Vermont Safety Developments LLC
The PTAB denied institution of the IPR petition filed by Head Sport GmbH against Vermont Safety Developments LLC regarding ski binding systems. The denial hinged on the Petitioner's failure to establish a reasonable likelihood of prevailing without an agreed-upon claim construction for 'release logic.'
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom settled their dispute over a continuous glucose monitoring patent, leading the PTAB to terminate the IPR by joint request.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care challenged DexCom's CGM patents in an IPR, arguing the claims are obvious over prior art combining Yarger and Love. The Board granted institution after claim construction, finding a reasonable likelihood of unpatentability for at least one claim.
Curtis Industries, LLC et al. v.B & D TECHNOLOGIES LLC
Curtis Industries and B&D Technologies settled their inter partes review of U.S. Patent 10,632,815 before the Board instituted a trial. The Board granted the joint motion to terminate and treated the settlement agreement as confidential.
PrimeSource Building Products, Inc. v.National Nail, Corp.
PrimeSource Building Products and National Nail settled their IPR dispute over U.S. Patent 10,378,218 before the Board instituted a trial. The Board granted the joint motion to terminate and kept the settlement agreement confidential.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom settled their IPR dispute, leading the PTAB to terminate the proceeding. The settlement agreement was deemed confidential business information.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom settled their dispute over DexCom’s glucose‑monitoring patent, leading the PTAB to terminate the IPR. The settlement agreement was deemed confidential business information.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care successfully petitioned to institute IPR proceedings against DexCom for patent infringement related to remote patient monitoring and glucose technology. The Board found a reasonable likelihood of prevailing on multiple grounds, specifically finding that prior art combinations rendered key claims obvious under 35 U.S.C. § 103.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care Inc. successfully petitioned to challenge DexCom's CGM patent (9119528) on grounds of anticipation and obviousness over Brauker. The Board found a reasonable likelihood of unpatentability for the challenged claims, leading to institution.
Champion Laboratories, Inc. et al. v.HENGST SE
The Petitioner failed to prove that the challenged claims of Patent No. 9,023,203 B2 were unpatentable by obviousness over prior art references Yokoyama, Cline, and Honermann. The Board found insufficient motivation for a Person of Ordinary Skill in the Art (POSITA) to make the claimed structural modifications or reorient existing devices.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.